{"id":4381,"date":"2019-01-11T11:12:18","date_gmt":"2019-01-11T10:12:18","guid":{"rendered":"https:\/\/patientenstimme-sma.de\/?page_id=4381"},"modified":"2026-03-16T21:04:50","modified_gmt":"2026-03-16T20:04:50","slug":"neue-infomationen-zu-risdiplam","status":"publish","type":"post","link":"https:\/\/smartunity.space\/stories\/thema\/neue-infomationen-zu-risdiplam\/","title":{"rendered":"Neue Infomationen zu Risdiplam"},"content":{"rendered":"\n<div class=\"wp-block-group alignwide has-subtle-background-color has-background is-layout-flow wp-block-group-is-layout-flow\">\n<p class=\"tw-text-wide\">Vom 07. &#8211; 10. 01. 2019 fand in San Francisco die  <a rel=\"noreferrer noopener\" aria-label=\"37. Annual J.P. Morgan Healtcare Conference (\u00f6ffnet in neuem Tab)\" href=\"https:\/\/www.jpmorgan.com\/global\/healthcareconference\" target=\"_blank\">37. Annual J.P. Morgan Healtcare Conference<\/a> statt. In dessen Rahmen stellt <a rel=\"noreferrer noopener\" href=\"http:\/\/ir.ptcbio.com\/news-releases\/news-release-details\/ptc-therapeutics-provides-corporate-update-and-outlines-5-year\" target=\"_blank\">PTC<\/a> einen 5 Jahres-Strategieplan vor der auch ein paar Infos zu Risdiplam in petto hat.<\/p>\n\n\n\n<div class=\"wp-block-columns alignwide is-layout-flex wp-container-core-columns-is-layout-28f84493 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:100%\">\n<blockquote class=\"wp-block-quote is-style-default is-layout-flow wp-block-quote-is-layout-flow\"><p>Zitat: (per Tool \u00fcbersetzt)<\/p><p>Zulassungsantr\u00e4ge, die f\u00fcr das zweite Halbjahr 2019 anvisiert wurden, basieren auf j\u00fcngsten R\u00fcckmeldungen der FDA und der nationalen Gesundheitsbeh\u00f6rden in Europa, wonach Teil 1 von FIREFISH und SUNFISH ausreichen k\u00f6nnte, um NDA \/ MAA einzureichen<br>Das Ziel des klinischen Entwicklungsprogramms besteht darin, die Zulassung eines breiten Labels zu unterst\u00fctzen, sodass Risdiplam m\u00f6glicherweise so vielen SMA-Patienten wie m\u00f6glich zugute kommen kann.<\/p><cite>Quelle: <a href=\"https:\/\/www.prnewswire.com\/news-releases\/ptc-therapeutics-provides-corporate-update-and-outlines-5-year-strategic-plan-at-2019-jp-morgan-healthcare-conference-300773595.html\" target=\"_blank\" rel=\"noreferrer noopener\" aria-label=\"https:\/\/www.prnewswire.com\/news-releases\/ptc-therapeutics-provides-corporate-update-and-outlines-5-year-strategic-plan-at-2019-jp-morgan-healthcare-conference-300773595.html (\u00f6ffnet in neuem Tab)\">https:\/\/www.prnewswire.com\/news-releases\/ptc-therapeutics-provides-corporate-update-and-outlines-5-year-strategic-plan-at-2019-jp-morgan-healthcare-conference-300773595.html<\/a><\/cite><\/blockquote>\n<\/div>\n<\/div>\n\n\n\n<p class=\"tw-text-wide\">Es wei\u00dft also darauf hin, das zumindest versucht wird Risdiplam recht z\u00fcgig zur Zulassung und Verf\u00fcgbarkeit zu bringen.<\/p>\n\n\n\n<div class=\"wp-block-columns alignwide is-layout-flex wp-container-core-columns-is-layout-28f84493 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:100%\">\n<ul class=\"wp-block-list\"><li>Zur Unterst\u00fctzung anbei ein direkter <a href=\"https:\/\/translate.google.com\/translate?hl=de&amp;sl=en&amp;tl=de&amp;u=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Fptc-therapeutics-provides-corporate-update-and-outlines-5-year-strategic-plan-at-2019-jp-morgan-healthcare-conference-300773595.html\" target=\"_blank\" rel=\"noreferrer noopener\" aria-label=\" (\u00f6ffnet in neuem Tab)\">Link \u00fcber Google Translate<\/a><\/li><\/ul>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Vom 07. &#8211; 10. 01. 2019 fand in San Francisco die 37. Annual J.P. Morgan Healtcare Conference statt. In dessen Rahmen stellt PTC einen 5 Jahres-Strategieplan vor der auch ein paar Infos zu Risdiplam in petto hat. Zitat: (per Tool \u00fcbersetzt) Zulassungsantr\u00e4ge, die f\u00fcr das zweite Halbjahr 2019 anvisiert wurden, basieren auf j\u00fcngsten R\u00fcckmeldungen der [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"only-view","format":"standard","meta":{"activitypub_content_warning":"","activitypub_content_visibility":"","activitypub_max_image_attachments":0,"activitypub_interaction_policy_quote":"anyone","activitypub_status":"","footnotes":""},"categories":[1],"tags":[58],"class_list":["post-4381","post","type-post","status-publish","format-standard","hentry","category-thema","tag-smanews"],"_links":{"self":[{"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/posts\/4381","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/comments?post=4381"}],"version-history":[{"count":1,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/posts\/4381\/revisions"}],"predecessor-version":[{"id":39883,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/posts\/4381\/revisions\/39883"}],"wp:attachment":[{"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/media?parent=4381"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/categories?post=4381"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/tags?post=4381"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}